BTIG Raises Price Target for Biohaven to $60 Amid Analyst Optimism

BTIG has raised its price target for Biohaven (BHVN) to $60, maintaining its "Buy" rating. This reflects a 1.69% increase in the price target and aligns with the company's prospects as of August 19, 2025. Analyst Thomas Shrader is optimistic about Biohaven's growth trajectory. Other analysts have provided mixed ratings, with some lowering their price targets and maintaining their "Buy" or "Outperform" ratings. The average target price for Biohaven is $45.85, with a high estimate of $75.00 and a low estimate of $19.00, indicating a potential upside of 191.83% from the current price.

BTIG analyst Thomas Shrader has raised the firm's price target on Biohaven (BHVN) to $60 from $59, maintaining a "Buy" rating. This 1.69% increase reflects the analyst's optimism about Biohaven's growth trajectory, particularly in light of the company's ongoing clinical trials and regulatory approvals [1].

Biohaven is a biopharmaceutical company focused on immunology, neuroscience, and oncology. Its lead candidate, VYGLXIA (troriluzole), is under review by the FDA for treating spinocerebellar ataxia/SCA, a rare, progressive, and fatal neurological disease. Analysts have noted that the regulatory timeline for troriluzole in SCA has been reaffirmed, with the PDUFA date still scheduled in Q4 2025, and the company is preparing for a potential commercial launch [2].

Other analysts have provided mixed ratings for Biohaven. Leerink lowered the firm's price target to $50 from $60, while keeping an "Outperform" rating on the shares following the Q2 2025 earnings report and incremental updates on the pipeline [2]. The average target price for Biohaven is $45.85, with a high estimate of $75.00 and a low estimate of $19.00, indicating a potential upside of 191.83% from the current price [2].

Outlook Therapeutics, another biopharmaceutical company, has recently reported financial results for the third quarter of fiscal year 2025, showing initial commercial sales of LYTENAVA™ (bevacizumab gamma) in Europe. This marks the beginning of the company's transformation into a commercial entity [3].

References:
[1] https://www.tipranks.com/news/the-fly/biohaven-price-target-raised-to-60-from-59-at-btig-thefly
[2] https://finance.yahoo.com/news/leerink-lowers-biohaven-bhvn-pt-034103424.html
[3] https://finance.yahoo.com/news/outlook-therapeutics-reports-financial-results-120500610.html